Back

Association of pulse pressure with risk of major adverse cardiovascular events among cardiovascular outcome trial participants

26 August 2023 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Hypertension phenotypes and arterial stiffness Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Luke Joseph Laffin

Cleveland Clinic, Cleveland (United States of America)

6 More presentations in this session

Presentation thumbnail
Arterial stiffness, blood pressure progression and penile vascular disease in males with erectile dysfunction: a closer look at microcirculatory damage
Doctor D. Terentes-Printzios (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Arterial stiffness assessment in patients with resistant hypertension using pulse wave analysis
Miss A. Akhmimi (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Comparison of pulse wave velocity and hypertensive response to exercise in predicting incidence of resistant hypertension
Doctor B. Braganca (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Central systolic blood pressure as a risk for the accelerated progression of arterial stiffness
Doctor T. Takahashi (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Central Blood Pressure predicts the future cardiovascular risk better than peripheral Blood Pressure: the northern shanghai study
Associate Professor Y. Zhang (Shanghai, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertension phenotypes and arterial stiffness

The Event

Event poster

ESC Congress 2023

26 August 2023 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Pulse pressure as a prognostic value for normotensive inferior STEMI patients
thumbnail
Congress Presentation
Carotid-Femoral pulse wave velocity progression in hypertensive patients is associated with subsequent cardiovascular outcomes
thumbnail
Congress Presentation
Association of systolic blood pressure and pulse pressure with 30-days cardiovascular mortality and heart failure rehospitalization in patients with heart failure with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources